|
1
|
Robert Koch Institute the Association of
Population-based Cancer Registries in Germany: Cancer in Germany
2009/2010. 2014.
|
|
2
|
Jin H, Pinheiro PS, Callahan KE and
Altekruse SF: Examining the gastric cancer survival gap between
Asians and whites in the United States. Gastric Cancer. 20:1–10.
2016.PubMed/NCBI
|
|
3
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alderson D, Langley RE, Nankivell MG,
Blazeby JM, Griffi M, Crellin A and Cunningham D: Neoadjuvant
chemotherapy for resectable oesophageal and junctional
adenocarcinoma: results from the UK Medical Research Council
randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol. 33
suppl:abstr 4002. 2015.
|
|
5
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D: ESMO Guidelines Committee: Gastric
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 suppl 5:v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayakawa M and Kojima Y:
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of
advanced gastric cancer in adults when given in combination with
cisplatin: A review comparing it with other fluoropyrimidine-based
therapies. Onco Targets Ther. 4:193–201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ajani JA, Rodriguez W, Bodoky G,
Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
Lang I and Falcon S: Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced
gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.
J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahlberg R, Lorenzen S, Thuss-Patience P,
Heinemann V, Pfeiffer P and Möhler M: New Perspectives in the
Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU
Therapy in Combination with Cisplatin. Chemotherapy. 62:62–70.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kunisaki C, Makino H, Kimura J, Takagawa
R, Kanazawa A, Ota M, Kosaka T, Ono HA, Akiyama H and Endo I:
Impact of S-1 plus cisplatin neoadjuvant chemotherapy on scirrhous
gastric cancer. Oncology. 88:281–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okabe H, Hata H, Ueda S, Zaima M, Tokuka
A, Yoshimura T, Ota S, Kinjo Y, Yoshimura K and Sakai Y: Kyoto
University Surgical Oncology Group (KUSOG): A phase II study of
neoadjuvant chemotherapy with S-1 and cisplatin for stage III
gastric cancer: KUGC03. J Surg Oncol. 113:36–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; NY: 2010
|
|
14
|
Common Terminology Criteria for Adverse
Events (CTCAE). Version 4.0, published May. 2009.https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfApril
23–2017
|
|
15
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chuah B, Goh BC, Lee SC, Soong R, Lau F,
Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, et al: Comparison of
the pharmacokinetics and pharmacodynamics of S-1 between Caucasian
and East Asian patients. Cancer Sci. 102:478–483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric Cancer, Version 3.2016, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moehler M, Al-Batran SE, Andus T, Anthuber
M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, et
al: AWMF: German S3-guideline ‘Diagnosis and treatment of
esophagogastric cancer’. Z Gastroenterol. 49:461–531. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lorenzen S, Pauligk C, Homann N,
Schmalenberg H, Jäger E and Al-Batran S-E: Feasibility of
perioperative chemotherapy with infusional 5-FU, leucovorin, and
oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly
patients with locally advanced esophagogastric cancer. Br J Cancer.
108:519–526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yun J, Lee J, Park SH, Park JO, Park YS,
Lim HY and Kang WK: A randomised phase II study of combination
chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or
cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J
Cancer. 46:885–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Al-Batran S-E, Hartmann JT, Probst S,
Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G,
Homann N, Wilhelm G, et al: Arbeitsgemeinschaft Internistische
Onkologie: Phase III trial in metastatic gastroesophageal
adenocarcinoma with fluorouracil, leucovorin plus either
oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft
Internistische Onkologie. J Clin Oncol. 26:1435–1442. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bando H, Yamada Y, Tanabe S, Nishikawa K,
Gotoh M, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Efficacy and safety of S-1 and oxaliplatin combination therapy in
elderly patients with advanced gastric cancer. Gastric Cancer.
19:919–926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa K, Yamada Y, Ishido K, et al:
Impact of progression type on overall survival in patients with
advanced gastric cancer based on randomized phase III study of S-1
plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer.
2016.
|
|
26
|
Burakgazi AZ, Messersmith W, Vaidya D,
Hauer P, Hoke A and Polydefkis M: Longitudinal assessment of
oxaliplatin-induced neuropathy. Neurology. 77:980–986. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ajani JA, Buyse M, Lichinitser M,
Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha
R, Carrato A, et al: Combination of cisplatin/S-1 in the treatment
of patients with advanced gastric or gastroesophageal
adenocarcinoma: Results of noninferiority and safety analyses
compared with cisplatin/5-fluorouracil in the First-Line Advanced
Gastric Cancer Study. Eur J Cancer. 49:3616–3624. 2013. View Article : Google Scholar : PubMed/NCBI
|
